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Summary
Cellular senescence is a stable cell cycle arrest, caused by insults,
such as: telomere erosion, oncogene activation, irradiation, DNA
damage, oxidative stress, and viral infection. Extrinsic stimuli
such as cell culture stress can also trigger this growth arrest.
Senescence is thought to have evolved as an example of
antagonistic pleiotropy, as it acts as a tumor suppressor mech-
anism during the reproductive age, but can promote organismal
aging by disrupting tissue renewal, repair, and regeneration later
in life. The mechanisms underlying the senescence growth arrest
are broadly considered to involve p16INK4A-pRB and p53-p21CIP1/
WAF1/SDI1 tumor suppressor pathways; but it is not known what
makes the senescence arrest stable and what the critical down-
stream targets are, as they are likely to be key to the establish-
ment and maintenance of the senescent state. MYB-related
protein B (B-MYB/MYBL2), a member of the myeloblastosis
family of transcription factors, has recently emerged as a
potential candidate for regulating entry into senescence. Here,
we review the evidence which indicates that loss of B-MYB
expression has an important role in causing senescence growth
arrest. We discuss how B-MYB acts, as the gatekeeper, to
coordinate transit through the cell cycle, in conjunction with
the multivulval class B (MuvB) complex and FOXM1 transcription
factors. We also evaluate the evidence connecting B-MYB to the
mTOR nutrient signaling pathway and suggest that inhibition of
this pathway leading to an extension of healthspan may involve
activation of B-MYB.
Key words: aging; B-MYB; cellular senescence; growth arrest;
MuvB.
Introduction
Cellular senescence, originally described as a form of cell aging, is a
stable cell cycle arrest caused by insults including telomere erosion,
oncogene activation, irradiation, DNA damage, oxidative stress, viral
infection, and toxins (Ben Porath & Weinberg, 2004; Collado et al.,
2007; Vaughan & Jat, 2011; Lopez-Otın et al., 2013). Extrinsic stimuli
such as cell culture stress can also trigger this programmed growth
arrest. These stressors induce a complex stress response that results in
the activation of two well-known tumor suppressors, p53 and pRB
(retinoblastoma susceptibility protein; Ryan et al., 2001). Upon activa-
tion, p53 upregulates the cyclin-dependent kinase inhibitor, p21CIP1/
WAF1/SDI1, that inhibits the Cyclin A-, Cyclin E-, and Cyclin D-dependent
kinase complexes (Lowe & Sherr, 2003). CyclinD-CDK4/6, CyclinE-CDK2,
and CyclinA-CDK2 normally phosphorylate and inactivate pRB, and this
is prevented by p21CIP1/WAF1/SDI1 (Lowe & Sherr, 2003). Dephosphoryl-
ated pRB represses the G1/S transition by sequestering E2F transcription
factors, thereby inhibiting E2F-dependent gene expression (Ben-Porath &
Weinberg, 2005; Di Micco et al., 2008). The p107 and p130 pRB-like
pocket proteins associate with E2Fs and MuvB core proteins to form the
DREAM [dimerization protein (DP), RB-like, E2F, and MuvB] complex that
represses all cell cycle-dependent genes upon quiescence (Sadasivam
et al., 2012; DeCaprio, 2013; Sadasivam & DeCaprio, 2013). The pRB
pathway may also be activated independently of p53 via upregulation of
p16INK4A, which inhibits CyclinD–CDK4/6 complexes from specifically
phosphorylating and inactivating pRB (Rufini et al., 2013). The tumor
suppressor, p53, is a master transcription factor that exerts control over
global transcriptional networks and therefore also induces senescence by
alternative pathways (Rufini et al., 2013). Persistent activation of the p53
and pRB pathways results in cellular senescence, a phenomenon
commonly associated with biological aging.
Senescence, cancer, and aging
Senescence is thought to have evolved as an example of antagonistic
pleiotropy, as it provides beneficial traits during the reproductive age of
an individual, but confers deleterious effects later on in life (Campisi,
2005, 2013). This is because, when organisms are young, senescence
acts as a tumor suppressor mechanism through the removal of
genetically unstable cells or cells that have acquired an oncogenic
mutation, by inhibiting their proliferation (oncogene-induced senes-
cence) (Campisi, 2005, 2013); replicative immortality gained through the
bypass of cellular senescence is thus a key hallmark of cancer cells.
However, later in life, senescence promotes organismal aging via the
disruption of tissue renewal, repair, and regeneration and the accumu-
lation of nondividing (senescent) cells (Kuilman et al., 2008).
The loss of proliferative potential with age should suppress cancer,
but cancer incidence, like other degenerative diseases of aging, increases
nearly exponentially with age. There is now increasing evidence that the
increase in cancer incidence is due to senescent cells secreting factors
that create a tissue microenvironment that promotes tumor formation.
Senescent cells secrete a plethora of inflammatory cytokines, chemo-
kines, and matrix metalloproteinases such as stromelysin (MMP3), as part
of the senescence-associated secretory phenotype (SASP) proteins. The
SASP proteins promote epithelial-to-mesenchymal transition as well as
the degradation of basement membranes, thereby increasing cell
migration, invasion, and metastasis. As a result, this activates immune
cells causing the engulfment of surrounding tissue, resulting in tissue
degradation (Tchkonia et al., 2013). Senescent cells also secrete factors
such as WNT16B, interleukin-6 (IL-6), and tissue inhibitor of metallopro-
teinases-1 (TIMP-1) that can protect neighboring tumor cells from being
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killed (Gilbert & Hemann, 2010; Sun et al., 2012). SASP inflammatory
proteins can also induce areas of local inflammation; cumulatively, this
promotes an aging pathology and chronic age-related diseases through
the disruption of tissue architecture and function (Longo & Finch, 2003;
Kuilman et al., 2008). Senescence has been strongly associated with
age-related diseases such as type II diabetes, cardiovascular disease, and
neurodegenerative disease, three of the world’s largest killers (Golde &
Miller, 2009; Khan et al., 2012; Monickaraj et al., 2013). A meta-
analysis of genome-wide association studies and age-associated diseases
has identified two highly significant peaks of disease association,
mapping to the major histocompatibility locus and the INK4/ARF locus
(Jeck et al., 2012). Senescence has hence been flagged as a novel target
against aging and its related pathologies, as it may potentially be more
beneficial to treat the underlying cause of these diseases (aging) rather
than treating their symptoms individually. This has led to the idea that
antisenescence therapy could lead to an extension of human healthspan.
Although in its infant stage, the promotion of antisenescence mecha-
nisms has already been shown to decrease the onset of age-related
pathology in vivo, whilst the clearance of p16INK4A-positive senescent
cells leads to an increase in healthspan (Longo & Finch, 2003; Baker
et al., 2011; Huang et al., 2011). However, little is known about the
critical molecular targets, downstream of p53 and pRB, that are specific
to the senescent cell fate and what makes the senescence growth arrest
stable. Moreover, much of the focus behind defining such targets has
been around genes that are upregulated during senescence and are
direct inducers, rather than genes that are inhibited during this process;
such knowledge is imperative to the development of therapeutics and
strategies that ameliorate the degenerative pathologies of aging.
B-MYB
A recently emerging candidate that seems to play a role in attenuating
senescence is B-MYB. B-MYB, a member of the myeloblastosis family of
transcription factors, is present in all vertebrates and has vital
antisenescence qualities due to its role in cell proliferation and growth
(Martinez & DiMaio, 2011). Transcription of B-MYB occurs mainly at the
onset of S-phase and is functionally activated by the CyclinA–CDK2
complex (Lefebvre et al., 2010; Down et al., 2012). The MYB family of
ubiquitously expressed transcription factors (TFs) is comprised of three
isoforms, A-MYB, B-MYB, and C-MYB. C-MYB was the first to be
discovered when it was found to be the oncogene present in avian
myeloblastosis virus, which causes acute myeloblastic leukemia and can
transform hematopoietic cells in culture; A- and B-MYB were subse-
quently cloned via homology to C-MYB (Roussel et al., 1979; Lam et al.,
1992). The literature surrounding MYB proteins is therefore skewed
toward their oncogenic potential; very little attention has been focused
on their antisenescence properties particularly those of B-MYB.
MYB isoforms have distinct biological roles, as demonstrated by their
dissimilar patterns of gene expression (Rushton et al., 2003). One
property, crucial to the exclusivity of B-MYB and its antisenescence role,
is that unlike the otherMYB isoforms, B-MYB is expressed in all replicating
cells and is strongly associated with cell cycle progression (Ness, 2003).
This is related to it being regulated transcriptionally by the pocket proteins
and E2F transcription factors (Lam&Watson, 1993), as well as its ability to
interact with the MuvB core complex (Quaas et al., 2012).
The DREAM complex and cell cycle progression
During quiescence, the MuvB complex, comprised of LIN9, 37, 52, 54 as
well as RBBP4, forms the DREAM complex upon association with p107/
p130 RB-like pocket proteins and E2F4–DP1, which represses E2F-
dependent genes (Fig. 1) (Sadasivam & DeCaprio, 2013). High p53 levels
also induce a shift in MuvB core-associated proteins from B-MYB to
p130/E2F4/DP1 (Quaas et al., 2012). However, upon cell cycle entry,
p130 dissociates from the MuvB core and from E2F-dependent
promoters, permitting activator E2Fs to transactivate G1-/S-phase genes
(Longo & Finch, 2003; Sadasivam et al., 2012). The MuvB core then
binds to B-MYB to form the B-MYB–MuvB complex that associates with
the promoters of genes expressed later in S-phase. This complex in turn
recruits FOXM1, a forkhead transcription factor, to these promoters
during G2, enabling FOXM1 to activate expression of a range of genes
such as Cyclin B, survivin, cdc25b phosphatase, and Aurora B kinase that
are important for the G2–M transition (Fig. 1) (Lefebvre et al., 2010;
Martinez et al., 2011; Down et al., 2012; Sadasivam et al., 2012;
Sadasivam & DeCaprio, 2013). The MuvB core within these complexes is
essential for targeting them to the promoters of specific sets of cell cycle-
dependent genes (Sadasivam & DeCaprio, 2013).
FOXM1 is a highly conserved forkhead transcription factor vital for cell
cycle progression (Katoh et al., 2013). Its expression is induced when
quiescent cells reenter the cell cycle and reach a maximal level in S-phase
that is maintained throughout G2 and mitosis. FOXM1 is downregulated
upon replicative senescence in primary human fibroblasts (Hardy et al.,
2005). Its expression is markedly reduced in cells from elderly patients as
well as patients with progeria (Ly et al., 2000), and FOXM1-deficient
mouse embryo fibroblasts undergo premature senescence (Wang et al.,
2005). FOXM1 is a critical target of the CyclinD-CDK4/6 kinases; this
phosphorylation leads to its stabilization and activation, thereby main-
taining its expression and suppressing the levels of reactive oxygen species
(Anders et al., 2011). More recent studies suggest that the activation of
FOXM1 could have a role in reducing skin aging by inhibiting UVB-induced
senescence (Ling et al., 2014). FOXM1 can also override genotoxic agent-
induced senescence by modulating expression of DNA damage repair
genes (Khongkow et al., 2013). As B-MYB is vital for the effects of
FOXM1, this suggests that B-MYB may also play a role in preventing
senescence through cell cycle progression. B-MYB is also implicated in the
regulation of FOXM1 transcription, as depletion of B-MYB reduces
FOXM1 expression and several other G2/M-specific genes in mouse
fibroblasts (Down et al., 2012). Interestingly, B-MYB is also a target gene
of FOXM1 and involved in complex cross-regulation with FOXM1 (Down
et al., 2012). Although B-MYB exerts its main effects on the G2 stage of
the cell cycle, it also increases transcription of genes important for S- and
M-phase such as DNA topoisomerase by binding to MYB binding sites
(MBSs) in their gene promoters (Martinez & DiMaio, 2011). B-MYB has
been shown to be essential for S-phase progression and genomic stability
in diploid and polyploid megakaryocytes, as B-MYB siRNAs reduced the
number of cells that underwent DNA replication (Garcıa & Frampton,
2006). B-MYB also forms a complex with clathrin and filamin (MYB–Clafi
complex) that is required for mitotic spindle function and therefore the
G2–M transition (Yamauchi et al., 2008). Moreover, B-MYB is expressed
in all dividing cells and acts to suppress the cyclin-dependent kinase
inhibitor p16INK4A (Huang et al., 2011). B-MYB therefore exerts extensive
control over the cell cycle, whereas the effects of FOXM1 are limited to
G2-/M-phase gene expression (Martinez & DiMaio, 2011). This suggests
that B-MYB could be a more potent cell cycle progression gene than
FOXM1, highlighting a potential role in preventing senescence.
B-MYB and Cellular senescence
The role of B-MYB in cell cycle progression has led it to being commonly
associated with tumor progression, leading to its role in cellular
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senescence being ignored. However, there is strong evidence to indicate
that B-MYB is inhibited during senescence (Lin et al., 1994; Hardy et al.,
2005; Martinez & DiMaio, 2011; Rovillain et al., 2011). Hardy and
colleagues used cDNA microarrays to identify genes that were differen-
tially expressed when conditionally immortal HMF3A fibroblasts under-
went senescence growth arrest, followed by in silico promoter analysis of
the differential genes and electrophoretic mobility shift assays (Hardy
et al., 2005). Rovillain et al. (2011) extended this study using genome-
wide expression profiling, in conjunction with inactivation of the p16
INK4A-pRB and p53-p21CIP1/WAF1/SDI1 tumor suppressor pathways, in
HMF3A cells, to identify genes that were downregulated upon senes-
cence. This data, coupled to bioinformatic transcription factor analysis,
revealed that B-MYB was one of the most highly downregulated
transcription factors upon senescence. Upon further investigation, we
found that ectopic expression of B-MYB bypasses senescence in HMF3A
cells; in fact, B-MYB expression bypasses senescence more efficiently
than FOXM1 (S.N. Mowla, P.S. Jat, unpublished data) suggesting that
loss of B-MYB expression may have a causative role in senescence.
The first evidence implicating a causal role of B-MYB in cellular
senescence was obtained by Lin et al. (1994) who constitutively
expressed B-MYB in a human cell line, leading to a bypass of p53-
p21CIP1/WAF1/SDI1-induced G1 arrest, even in the presence of CyclinE-
CDK2 kinase inhibitors. Moreover, constitutive expression of B-MYB in
BALB/c 3T3 fibroblasts reduced their growth factor requirement (Sala &
Calabretta, 1992) and induced DNA synthesis in p107 growth-arrested
human osteosarcoma cells (Sala et al., 1996). More definitive evidence,
indicating a causal role of B-MYB in cellular senescence rather than
quiescence, derives from Masselink et al. (2001) who showed that
B-MYB expression could rescue oncogene-induced premature senes-
cence caused by an activated ras oncogene in rodent cells. Moreover,
siRNA silencing of B-MYB leading to reduced expression induced
senescence in primary human foreskin fibroblasts and HeLa cervical
cancer cells (Johung et al., 2007). Taken together, these results suggest
that B-MYB impedes cellular senescence. However, it remains to be
determined how B-MYB blocks senescence and how it is integrated into
senescence-inducing pathways.
Senescence pathways
One way in which B-MYB represses senescence is through inhibition of
the p16INK4A-pRB pathway (Fig. 2) (Sala & Calabretta, 1992; Yamauchi
et al., 2008; Martinez et al., 2011). B-MYB expression is accompanied
by Cyclin D1 expression (Sala & Calabretta, 1992). Other research
indicates that B-MYB is also a transcriptional repressor, as its expression
in embryonic lung fibroblasts leads to repression of p16INK4A, delaying
cellular aging and increasing replicative lifespan; whereas knockdown of
B-MYB expression increases expression of p16INK4A, thereby inducing
cellular senescence (Huang et al., 2011). It can thus be suggested that B-
MYB inhibits p16INK4A leading to the activation of CyclinD-CDK4/6 and
phosphorylation and inactivation of pRB. PRB has been reported to
repress B-MYB expression during quiescence as well as senescence;
however, the repression is much stronger during senescence due to the
activation of the miR-29 and miR-30 families of microRNAs that strongly
repress B-MYB expression (Martinez et al., 2011). Therefore, it can be
hypothesized that extremely low levels of B-MYB lead to cellular
senescence and this is achieved by negative feedback between pRB and
B-MYB. When pRB represses B-MYB to moderately low levels, this leads
to quiescence, but when pRB also activates microRNAs resulting in very
low levels of B-MYB and therefore less inhibition of pRB, this leads to
senescence.
Our data indicates that the effects of B-MYB expression on bypassing
senescence are greater than inhibition of pRB by adenovirus E1A, HPV
Fig. 1 A model for how the MuvB core complex interacts with B-MYB, FOXM1, and p130–E2F4–DP1 to regulate cell cycle progression and entry into senescence. The MuvB
core complex functions as a cofactor/adaptor for different transcription complexes to regulate gene expression. In quiescence, p130/p107 associates with E2F4 and DP to
form the DREAM complex that represses all cell cycle-dependent gene expression (Sadasivam et al., 2012; DeCaprio, 2013; Sadasivam & DeCaprio, 2013). Upon entry into
the cell cycle, p130 dissociates from the MuvB core and from E2F-dependent promoters, permitting activator E2Fs to transactivate G1-/S-phase genes (Longo & Finch, 2003;
Sadasivam et al., 2012). The MuvB complex binds to B-MYB during S-phase and regulates expression of late S-phase genes. During G2, the MuvB–B-MYB complex recruits
FOXM1, to these promoters (Lefebvre et al., 2010; Down et al., 2012; Sadasivam et al., 2012; Sadasivam & DeCaprio, 2013). While B-MYB undergoes phosphorylation-
dependent, proteasome-mediated degradation, FOXM1 is activated through phosphorylation. Hyperphosphorylated FOXM1 remains bound to the MuvB complex and
modulates expression of a range of genes such as Cyclin B, survivin, cdc25b phosphatase, and Aurora B kinase that are important for the G2–M transition (Lefebvre et al.,
2010; Martinez et al., 2011; Down et al., 2012; Sadasivam et al., 2012). In senescence, both B-MYB and FOXM1 are lost and the MuvB complex recruits the transcriptionally
repressive p130/p107–E2F4–DP complex, to form the DREAM complex, to restrict expression of both early and late cell cycle genes essential for cell cycle reentry.
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E7, and E2F-DB, suggesting that B-MYB must also be acting upon other
targets in senescence. One possible candidate is p53 because, as
mentioned above, one critical activity p53 engages in, to arrest the cell
cycle, is shifting the MuvB core-associated proteins from B-MYB to p130/
E2F4/DP1 (Quaas et al., 2012). Our data reveal that ectopic expression of
B-MYB bypasses senescence in HMF3A cells in which activation of p53 is
the major pathway for inducing senescence (S.N. Mowla, P.S. Jat,
unpublished data). However, questions still remain as to how B-MYB
inhibits activated p53 and whether it inhibits the transcription of p53 or
acts downstream. One possibility is that high levels of B-MYB may
prevent the displacement of B-MYB by p130 in MuvB complexes.
Taken together, it can be postulated that high levels of B-MYB are
required for cell proliferation, aided via its effects on FOXM1, and that
the levels of B-MYB may therefore be a deciding factor in switching the
fine balance between proliferation, quiescence, and cellular senescence.
Shedding further light on the MuvB complex, its interaction with B-MYB
and FOXM1 and whether these three components are present in the
same complex simultaneously would be important in determining
how B-MYB interacts and engages with senescence pathways. However,
B-MYB may also be interacting with other as yet unknown pathways
involved in senescence.
Cell death
B-MYB has also been reported to play a role in cell death. Most studies
suggest that B-MYB promotes cell survival through the regulation of
apoptotic genes (Sala, 2005). For example, overexpression of B-MYB in
CTLL-2 cells causes resistance against apoptosis induced by DNA-
damaging agents such as doxorubicin (Grassilli et al., 1999). This is in
part due to an increased transcription of pro-survival genes, such as BCL2
and inhibition of apoptotic genes (Grassilli et al., 1999; Sala, 2005), but
is also due to an increase in resistance to DNA damage in B-MYB
expressing cells. B-MYB has been shown to increase genomic stability, as
cells lacking B-MYB are more sensitive to DNA damage induced by UV
radiation (Ahlbory et al., 2005). Equally, neuroblastoma cells expressing
high levels of B-MYB are resistant to UV-induced apoptosis (Schwab
et al., 2007). As DNA damage is a key activator of cellular senescence,
the role of B-MYB in protecting against such damage is therefore
consistent with a role of B-MYB in impeding senescence.
Development
Although senescence was originally identified as a stable cell cycle arrest,
it has now been shown that senescence is also a programmed
developmental mechanism that contributes toward mammalian embry-
onic development (Mu~noz-Espın et al., 2013; Storer et al., 2013). B-
MYB is robustly expressed in embryonic stem cells and has been reported
to sustain the self-renewal capacity of such cells (Zhan et al., 2012) by
promoting the genomic stability and survival of these cells. Silencing of
B-MYB in murine embryonic stem cells results in delayed transit through
G2/M, severe mitotic spindle and centrosome defects, polyploidy, and
differentiation-associated cell death (Tarasov et al., 2008). B-MYB is
therefore critical to the establishment of inner cell mass through cell
cycle progression and is vital in sustaining stem cell populations and self-
renewal capacity, two vital factors in the maintenance of tissue function,
and thus healthy aging.
Nutrient and metabolic signaling
B-MYB has very recently been implicated in nutrient signaling, and this
may be an important pathway that connects it to anti-aging signaling
(Fig. 2). During energy metabolism following food consumption, insulin
Fig. 2 Schematic illustration of the pathways linking B-MYB to Cellular Senescence and Aging. This indicates how loss of B-MYB expression results in senescence growth
arrest and thereby promotes aging. It also illustrates how oxidative/oncogenic stress, DNA damage, and dietary restriction may impinge upon senescence growth arrest and
aging via B-MYB.
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activates the receptor tyrosine kinase, insulin receptor (IR), which then
binds to the PTB domain of insulin receptor substrate 1 (IRS1), causing
the recruitment of PI3K to the cell surface. Here, PI3K (I) catalyses the
addition of a phosphate on the 30 position of PI(4,5)P2 using ATP to
generate PI(3,4,5)P3, which in turn recruits the serine/threonine kinase
AKT (PKB) to the cell membrane (Korkolopoulou et al., 2012). PI (3,4,5)
P3 brings AKT and the activating kinase of AKT, PDK1, in close proximity,
enabling PDK1 to partially activate AKT; mTORC2, then works in
conjunction with PDK1 to fully activate AKT. This results in the
phosphorylation and inactivation of glycogen synthase kinase 3b
(GSK3b), which normally inhibits glycogen synthesis; activation of this
pathway hence results in the storage of energy in the form of glycogen
(Morgensztern & McLeod, 2005). Interestingly, the bulk of literature
concerning anti-aging currently revolves around the inhibition of this
pathway through dietary restriction or rapamycin (Fig. 2); these are
currently among the hottest topics in aging research.
Rapamycin, an inhibitor of mTOR and therefore the mTOR pathway,
can extend lifespan in vitro and in vivo. For example, feeding mice with
rapamycin dramatically extends both female and male lifespan (Harrison
et al., 2009; Livi et al., 2013). Such treatment has also been reported to
reduce age-related disease as treating 24-month-old mice with rapa-
mycin-reversed age-related heart dysfunction (Flynn et al., 2013).
However, highly significant increases in longevity induced by the
inhibition of the mTOR pathway are not limited to mice, rather, such
effects have also been reported in other organisms (Jia et al., 2004;
Kapahi et al., 2004). More interestingly, rapamycin reduces oxidative
stress and premature senescence in vitro, leading to an increase in
replicative lifespan, thereby connecting this pathway to cellular senes-
cence and as a result, potentially to B-MYB (Li et al., 2012).
A potential pathway as to how mTOR could impinge upon the B-MYB
pathway has recently been discovered in Arabidopsis, although it
remains to be identified in mammals. It has been found that B-MYB is a
substrate for the GSK3-like kinase, BIN2, and phosphorylation by BIN2
stabilizes B-MYB (Ye et al., 2012). As mTOR can inhibit GSK3b, either
through mTORC2 acting in conjunction with AKT or by mTORC1 acting
further upstream, inhibition of mTOR using rapamycin could activate
B-MYB, leading to an extension in healthspan and lifespan. Other studies
suggest that mTOR may activate pRB by regulating upstream CDK
activity through p27KIP1 and Cyclin D1 (Mita et al., 2003) and as
described earlier, pRB and B-MYB are negative regulators of one
another. The inhibition of B-MYB downstream of mTOR, via pRB
activation, further supports the hypothesis that mTOR inhibition activates
B-MYB. Although the GSK3b pathway remains to be elucidated in
animals, the Arabidopsis results suggest a potential pathway linking
mTOR to B-MYB.
One currently popular theory, as to how rapamycin extends
lifespan, is somatic maintenance, which suggests that the inhibition
of mTOR leads to a reallocation of energy into the maintenance of
somatic cells (Fig. 2) (Masoro & Austad, 1996). As described above, B-
MYB acts to maintain genome stability and provide resistance against
DNA damage, thereby inhibiting cellular senescence. The energy
required for the maintenance of somatic cells by B-MYB could
potentially be gained through inhibition of mTOR, thereby coupling
energy metabolism and senescence signaling, two major pathways on
the road to aging.
Conclusions
B-MYB mediates a multitude of signaling pathways that affect cellular
senescence, cell growth, metabolism, and cell death and lies at the hub
of numerous signaling networks involved in these cellular behaviors.
Moreover, the levels of B-MYB regulated through p53 and pRB
determines the fine balance between proliferation, quiescence, and
senescence, making B-MYB a determinant of cell fate. This poses the
question that the increase in lifespan seen upon inhibition of mTOR may
be due to the upregulation of B-MYB and that the reallocation of energy
achieved from the inhibition of this pathway may be what permits B-
MYB to have an antisenescence role, in combination with its pro-cell
cycle activities. However, due to the oncogenic potential of B-MYB, very
little research has been performed to investigate the role of B-MYB in
aging. Future studies in vitro and in vivo, on how B-MYB integrates into
signaling pathways, in particular with mTOR in animal models, its
upstream and downstream effectors, and the effects of B-MYB on
cellular senescence and longevity, will be a promising new avenue for
anti-aging research.
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